Baidu
map

Cell:颠覆传统工艺!MIT“注水制造”生物药(抗菌肽、抗体、疫苗……)

2016-09-28 佚名 生物探索

导语:近日,MIT的科学家开发出一种工艺,让冷冻干燥的细胞成分再水化,可以生产出有用的蛋白质。该项目的亮点包括:在无细胞平台的现场按需制造生物分子;在无冷链的情况下运输和生产生物制品和生物分子;进行合成抗菌肽和疫苗的功能验证;组合制造抗体偶联物和小分子。近日,Cell在线报道了一项颠覆性的生物药制造工艺,麻省理工学院等机构的研究人员已经创造了一种微球冻干颗粒,包括所有需要将DNA转化为蛋白质的分子

导语:近日,MIT的科学家开发出一种工艺,让冷冻干燥的细胞成分再水化,可以生产出有用的蛋白质。该项目的亮点包括:在无细胞平台的现场按需制造生物分子;在无冷链的情况下运输和生产生物制品和生物分子;进行合成抗菌肽和疫苗的功能验证;组合制造抗体偶联物和小分子。

近日,Cell在线报道了一项颠覆性的生物药制造工艺,麻省理工学院等机构的研究人员已经创造了一种微球冻干颗粒,包括所有需要将DNA转化为蛋白质的分子机制,这将形成药物和疫苗按需生产的基础。



生产工艺展示图

试验中所使用的微球含有数十种酶和从细胞中提取的其它分子粒料,可在室温下存放很长的时间。然后向其中加入水和冷冻干燥的DNA,微球将产生由该DNA编码的蛋白质。

传统上,制造生物制剂类药物需要将编码活性蛋白的DNA导入活细胞中,然后在类似工厂的环境下大规模的增殖细胞,最后从大量细胞中提取出活性蛋白以制成产品。生产出来的生物制剂在被使用之前,必须始终处在冷藏状态中,这就大大限制了这些药物在许多地方的应用,而直接对生物制剂进行冷冻干燥也有可能会破坏其活性。

MIT生物工程与医学科学工程研究所(IMES)医学科学工程系的指导教授、该项目的资深作者 James Collins表示,这是可以编程的模块化系统,可以现场制作所需的产品,有数以百计的DNA颗粒可以添加进该系统。此外,这些直径仅有几毫米颗粒,却可以走向世界任何角落,不仅便于士兵、宇航员携带,还可以由医护人员带入偏远地区。

文章的主要作者包括多伦多大学助理教授、前哈佛大学威斯生物工程研究所研究科学家、IMES博士后Keith Pardee、威斯生物工程研究所研究科学家Jeong Wook Lee、威斯生物工程研究所研究人员Peter Nguyen。

无细胞合成

Collins教授和一些合成生物学家曾经通过设计的细胞来执行许多通常没有的功能,如生产药物或生物燃料。在过去的几年中,Collins教授发现这种设计还可以细胞外进行,通过提取必要的细胞成分和并在纸或其它材料冷冻干燥它们。无细胞提取物包括几十酶、DNA和RNA,以及核糖体和其他导致转录和翻译的分子机制。



在这项研究中,科学家是从方程式中整合出了论文,细胞提取物是简单地冷冻干燥成颗粒,保持稳定至少一年。在激活蛋白的生产时,研究人员只需添加水将微球再水化,冻干的DNA就可以编码出所需的蛋白质。

这种方法可以用来生产许多生物制剂类药物,包括药物、疫苗和抗体等等,甚至是可用于诊断疾病的分子标志物。

在Cell(《细胞》)上的报道中,研究人员制作了一种可以作为白喉疫苗的小蛋白以及具有潜在抗细菌感染的抗菌肽;此外,他们还程序化了产生酶的颗粒,可形成多步骤的代谢途径,合成一个称作“紫色素”的复杂药物,后者具有抗癌和抗菌活性;在诊断应用方面,研究人员利用微球产生了多种不同类型的抗体,其中一种可以检测结肠炎症患者体内的艰难梭菌。

便于贮存

由于冻干成分很容易储存和运输方便且不需要冷藏,因此这种方法比使用活细胞产生生物制药更方便。

没有参与该项研究的西北大学化学与生物工程系副教授Michael Jewett表示,Collins和他的同事们规划不久的将来,在无需冷[供应]链的情况下,冷冻干燥、无细胞生物制造平台可用于合成所需要的药物、疫苗和生物制品。这相当于将制造业从工厂转移到前线,甚至可以在目前无法到达的偏远地区,为患者提供专用的药物。

Collins教授预计,这种技术应该是非常有用的多样化装置。它可以设计成一个非常简单的随身携带的工具包,专供在发展中地区的卫生保健工作者使用;他还认为这对军事、远足甚至是长途旅行都是非常有用的。

Collins教授还补充道,这些颗粒也可以被纳入教育工具——类似于化学试剂的生物等效产品,你可以想象让学生使用这些微丸,在家里或学校进行合成生物学实验。

Collins教授还有一个想法,将颗粒放入“智能绷带”,用来检测感染,并产生合适的抗菌肽治疗感染。

“注水制造”生物药,前景令人激动

美国杨百翰大学副教授Bradley Bundy博士认为这项技术的前景令人激动:它让我们无需储存大量的疫苗和药物,而只需储存可以制造药物的装置就可以了,这更加经济和通用。他正在使用这种技术试图制造可以抗癌的蛋白药物。

研究人员承认,这一装置离真正投入实用还需要一定的时间。他们面临的困难包括如何提纯生产出来的生物制剂,如何获得无菌水,以及对使用者进行培训。不过,这项技术具有光明的前景,人道救援组织利用它可以快速向受自然灾害或疾病爆发的地区提供所需的药物,将来的宇航员们在太空旅行中可能也会离不开它。我们希望研究人员能早日将它推向市场。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2017-07-19 一叶知秋
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2017-04-29 仁心济世
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    继续关注!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959826, encodeId=1bac195982677, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 19 08:59:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869567, encodeId=6fe3186956eff, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 11 14:59:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900812, encodeId=57b31900812d2, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Apr 29 12:59:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330541, encodeId=221a133054129, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 30 00:59:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137466, encodeId=797413e46670, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:16:01 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137465, encodeId=170913e465a3, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 23:15:52 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    谢谢分享!

    0

相关资讯

Lancet Infect Dis:脊髓灰质炎粘膜免疫研究

对于全球根除脊髓灰质炎目标,识别限制脊髓灰质炎病毒复制的机制是至关重要的。目前通过口服脊髓灰质炎病毒或灭活脊髓灰质炎病毒(IPV)疫苗,以及混合计划下诱导的粘膜免疫(OPV)相关研究将告诉我们不同策略的不同阻断效果。我们对来自临床试验的样本进行了研究,对不同疫苗接种计划下的肠道免疫功能进行评估(通过粪便中的中和病毒和病毒特异性IgA浓度进行评估)。 FIDEC试验中,将拉丁美洲婴儿随机分为九

PNAS:放疗变身“癌症疫苗”联合中性粒细胞增强抗肿瘤免疫

根据西南医学中心研究人员进行的一项最新研究,将放射治疗和中性粒细胞刺激因子结合在一起能够增强抗肿瘤免疫。相关研究结果发表在国际学术期刊PNAS上。 放射治疗是三种癌症核心疗法中的一种。研究人员发现靶向肿瘤的放射治疗能够作为“癌症疫苗” 引起中性粒细胞介导的肿瘤细胞死亡,激发免疫系统对抗其他转移灶的癌细胞。 这也叫做“远端效应”,即放射治疗针对原位的癌细胞,随后导致未接受放射治疗的其他转

CMAJ:百日咳疫苗的有效性仅能维持数年

接种及未接种疫苗的人群百日咳复发病例的不断出现对疫苗的有效性提出了质疑,本研究旨在探究百日咳疫苗的有效性,以及免疫力减弱和全细胞免疫初始免疫的效果。2009年12月7日至2013年3月31日之间,研究人员共分析了5867名研究对象(486名测试阳性,5381名测试阴性)的数据。构建逻辑回归模型来计算比值比(ORs),疫苗的有效性计算为(1-OR)× 100。通过计算最后一次接种疫苗后患者每年百日咳

汇总|那些被疫苗“消灭”了的传染病

HPV(人乳头状瘤病毒)疫苗可以预防85%的HPV相关性癌症,由于疫苗的出现,以下这些疾病已经成为了过去式。1、小儿麻痹症(脊髓灰质炎)小儿麻痹症(脊髓灰质炎)是一种影响神经系统的传染性疾病,1979年美国本土已经消灭了脊髓灰质炎,这一切都要感谢Jonas Salk。1952年,他发明了脊髓灰质炎疫苗。到1990年代末,世界上80%的儿童已经接种过疫苗。如今,仍流行脊灰的国家由1988年的超过12

2016诺奖揭晓在即,近10年的生理学与医学奖得主都是何方神圣呢?

还有不到一个月的时间,一年一度的诺贝尔奖评选结果就要出炉了,想必大家已经迫不及待地想要知道今年生物和医学界究竟有哪些大牛能够脱颖而出了吧。诺贝尔生理学或医学奖在很长时间内已经成为公众中认识度最高的生物医学类奖项,一旦获此殊荣,即会成为举世瞩目的科学家,受到各国人民的膜拜。去年屠呦呦凭借青蒿素成为第一位获得诺贝尔科学奖项的中国本土科学家后,更加贴近了中国与诺贝尔奖的距离。下面,我们来一起重温一下

辟谣!关于疫苗的7大误解

导语:疫苗被科学界认为是20世纪最伟大的医学突破之一,它的出现让人类有能力与传染病对抗,是目前仅有的一种能够完全根除传染病流行的医学手段。作为生物制药的一个重要分支,疫苗能够阻断病毒、细菌的传播,是防控传染病发生和流行最经济、有效的措施之一。然而,并不是每个人都相信疫苗。虽然占少数,仍然有一些人对于疫苗的安全性和有效性持怀疑态度,特别是欧洲地区。根据一项最新研究显示,超41%的法国人认为疫苗是不安

Baidu
map
Baidu
map
Baidu
map